Histogen Inc.
HSTODelisted Oct 12, 2023- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001383701
Histogen Inc. was delisted on Oct 12, 2023; its insiders filed their last Form 4 on Jun 21, 2023; 9 institutions reported holding it in 13F filings for Q3 2023, worth $9.53K in total; no superinvestor held it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Histogen Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Histogen Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Kisner Daniel L | Director | – | Jun 21, 2023 | 0 |
| Fuhrmann Rochelle | Director | – | Jun 21, 2023 | 0 |
| Windham-Bannister Susan Richards | Director | – | Jun 21, 2023 | 0 |
| Crean David Hugh | Director | – | Jun 21, 2023 | 0 |
| Jackson Jonathan | Director | – | Jun 21, 2023 | 0 |
| Satz Brian | Director | – | Jun 21, 2023 | 0 |
| Reyes Joyce | See Remarks | – | Apr 28, 2023 | 0 |
| Mento Steven J | President and CEO | – | Mar 14, 2023 | 0 |
| Knudson Susan A. | COO and CFO | – | Mar 14, 2023 | 0 |
| Spada Alfred P. | See Remarks | – | Feb 27, 2023 | 0 |
| Latterich Martin | SVP, Technical Operations | – | Feb 22, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
No insider trades match these filters.